Vaxcyte Management
Management criteria checks 3/4
Vaxcyte's CEO is Grant Pickering, appointed in Nov 2013, has a tenure of 11.08 years. total yearly compensation is $12.14M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth €56.81M. The average tenure of the management team and the board of directors is 4.6 years and 5.6 years respectively.
Key information
Grant Pickering
Chief executive officer
US$12.1m
Total compensation
CEO salary percentage | 5.3% |
CEO tenure | 11.1yrs |
CEO ownership | 0.5% |
Management average tenure | 4.6yrs |
Board average tenure | 5.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$508m |
Jun 30 2024 | n/a | n/a | -US$497m |
Mar 31 2024 | n/a | n/a | -US$437m |
Dec 31 2023 | US$12m | US$640k | -US$402m |
Sep 30 2023 | n/a | n/a | -US$300m |
Jun 30 2023 | n/a | n/a | -US$265m |
Mar 31 2023 | n/a | n/a | -US$245m |
Dec 31 2022 | US$14m | US$601k | -US$223m |
Sep 30 2022 | n/a | n/a | -US$174m |
Jun 30 2022 | n/a | n/a | -US$143m |
Mar 31 2022 | n/a | n/a | -US$118m |
Dec 31 2021 | US$5m | US$575k | -US$100m |
Sep 30 2021 | n/a | n/a | -US$92m |
Jun 30 2021 | n/a | n/a | -US$87m |
Mar 31 2021 | n/a | n/a | -US$83m |
Dec 31 2020 | US$3m | US$481k | -US$89m |
Sep 30 2020 | n/a | n/a | -US$83m |
Jun 30 2020 | n/a | n/a | -US$73m |
Mar 31 2020 | n/a | n/a | -US$64m |
Dec 31 2019 | US$596k | US$426k | -US$50m |
Compensation vs Market: Grant's total compensation ($USD12.14M) is above average for companies of similar size in the German market ($USD4.83M).
Compensation vs Earnings: Grant's compensation has been consistent with company performance over the past year.
CEO
Grant Pickering (56 yo)
11.1yrs
Tenure
US$12,135,683
Compensation
Mr. Grant E. Pickering, M.B.A., is Co-Founder of Vaxcyte, Inc. since 2013 and has been its Chief Executive Officer and Director since November 2013 and served as its President since November 2013 until Dec...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 11.1yrs | US$12.14m | 0.53% € 56.8m | |
President & CFO | 4.6yrs | US$5.42m | 0.059% € 6.3m | |
Executive VP & COO | 5yrs | US$5.40m | 0.14% € 14.9m | |
Senior VP | 2.7yrs | US$3.49m | 0.0081% € 869.2k | |
Co-Founder | 11.9yrs | no data | no data | |
Co-Founder & VP of Research | no data | no data | no data | |
Senior VP of Finance & Principal Accounting Officer | 1.9yrs | no data | 0.0031% € 335.1k | |
Senior Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
Chief People Officer | less than a year | no data | no data | |
Senior Vice President of Process Development & Manufacturing | 8.7yrs | US$2.35m | no data | |
Senior Vice President of Commercial Manufacturing & Supply Chain | 3.1yrs | US$1.84m | no data | |
Senior Vice President of Project Management | no data | no data | no data |
4.6yrs
Average Tenure
55yo
Average Age
Experienced Management: 5VA's management team is considered experienced (4.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 11.1yrs | US$12.14m | 0.53% € 56.8m | |
Independent Director | 3.3yrs | US$704.22k | 0.0045% € 482.8k | |
Independent Director | 8.3yrs | US$696.72k | 0.010% € 1.1m | |
Independent Director | 6.6yrs | US$691.72k | 0.0045% € 482.8k | |
Independent Director | 4.7yrs | US$704.22k | 0.0045% € 482.8k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Chairman of the Board | 3.2yrs | US$724.22k | 0.0045% € 482.8k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
Independent Director | 3.3yrs | US$704.22k | 0.0045% € 482.8k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
5.6yrs
Average Tenure
57yo
Average Age
Experienced Board: 5VA's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/04 06:08 |
End of Day Share Price | 2024/09/06 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vaxcyte, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jason Matthew Gerberry | BofA Global Research |
Thomas Shrader | BTIG |
Louise Chen | Cantor Fitzgerald & Co. |